Bioventix Plc (LSE:BVXP) has spent two decades earning some of the fattest margins on the London Stock Exchange by selling sheep monoclonal antibodies to the world's largest diagnostics companies. Now its core products, led by a vitamin D antibody, are flat to declining, yet royalties from antibodies used in blood tests for Alzheimer's disease rose fivefold in the six months to 31 December 2025.

The question ahead of full-year results on 26 October 2026 is whether that neurology pipeline can grow fast enough to offset currency headwinds, pricing pressure in China and a troponin Franchise that has yet to deliver.

Interim results: Revenue slips, but Alzheimer's royalties surge

Bioventix published unaudited interim results on 30 March 2026 for the six months to 31 December 2025. Revenue fell to £6.16m from £6.73m, a decline of around 8%, while profit before tax eased to £4.85m from £5.05m. Basic EPS was 69.38p against 72.27p, the Interim Dividend was held at 70p and period-end cash was £5.3m.

Management blamed the weaker US dollar, noting that at constant 2024 exchange rates revenue would have been £6.4m and pre-tax profit £5.1m. It added that "challenging market conditions in China have led to the loss of some limited revenue streams", while vitamin D and other core antibody sales were "broadly in line" with the prior year.

The standout line was neurology. Royalties from tau antibodies used in Alzheimer's assays rose fivefold to £150k from £30k. Of the six leading in-vitro diagnostics companies Bioventix tracks, three now include its antibodies in their phospho-Tau217 assay designs, and three high-sensitivity platform companies use them in research-use-only tests. Chief executive Peter Harrison said: "We are increasingly confident that our progress in the development of SMAs for use in assays for the diagnosis of Alzheimer's disease and other neurological conditions will materialise in tangible commercial success." Trading remained in line with expectations for the year ending 30 June 2026.

A Royalty Business built on sheep antibodies

Bioventix creates and supplies sheep monoclonal antibodies, or SMAs, used as reagents in automated clinical blood tests run on analysers made by companies such as Roche, Siemens, Abbott and Beckman. It earns money two ways: physical sales of antibody material, and royalties on customers' Downstream sales of the tests that contain it. Because the antibodies are designed into regulator-approved assays, switching suppliers is costly and slow, giving Bioventix long-lived revenue streams from a base of just 14 staff.

Its largest product is the vitamin D antibody vitD3.5H10, which generated £6.6m of the £13.1m revenue in the year to 30 June 2025. Other core products cover thyroid, sex hormone, biotin-blocker and drugs-of-abuse testing, while a high-sensitivity troponin antibody supplied to Siemens for heart-attack testing is a second key stream. In FY25, £10.7m of sales came from outside the UK and EU, China contributed £2.4m, or 18%, and 50% to 60% of sales were dollar-linked.

Full-year FY25: margins intact, dividend above earnings

Results for the year ended 30 June 2025, published on 27 October 2025, showed revenue down 4% to £13.1m from £13.6m and profit before tax down 5% to £10.1m from £10.6m, a pre-tax Margin of around 77%. Basic EPS fell to 145.27p from 155.12p.

Beneath the headline, vitamin D antibody sales rose 12% to £6.6m, "slightly ahead of expectation", and tau/neuro sales increased fourfold from £155k to £605k, of which £75k was royalties. Offsetting this, biotin blocker sales fell 40% to £0.69m, drug-testing antibodies dropped 43% and "disappointingly, troponin sales have remained flat year on year".

R&D spending rose to £1.49m from £1.0m. Cash ended the year at £5.1m, down from £6.0m, after £8.19m of dividends. FY25 dividends totalled 150p per share, comprising a 70p first interim and an 80p second interim, against 155p a year earlier. That payout exceeded basic EPS, which explains the cash drawdown. At the 1,799p paid by chief financial officer Bruce Hiscock for 534 shares on 24 June 2026, the FY25 dividend equates to a trailing Yield of roughly 8.3%, and the 5,224,860 shares in issue imply a Market Value of about £94m.

What could drive the shares next?

The most obvious catalyst is the full-year results on 26 October 2026. The board guided in October 2025 that FY26 would see "a modest decline in revenues", and the March interims confirmed trading in line with that.

The second driver is blood-based Alzheimer's diagnostics. Bioventix antibodies already sit inside research-use-only pTau217 assays at three major IVD manufacturers. If those progress to clinically approved products, royalties would scale with test volumes on some of the largest installed analyser bases in the world.

Third is troponin. Siemens gained FDA approval in November 2024 for revised label claims covering a new prognostic use of its assay, and management said in October 2025 it remained "positive that troponin royalties will start to deliver growth in 2026 and beyond", though no uplift had appeared by December. A longer-dated option is the water-quality project, which uses caffeine and paracetamol levels as a surrogate for E. coli and was due to enter lateral-flow field trials in the second quarter of 2026.

Risks investors should watch

Revenue is concentrated in a handful of products and customers, and the largest, vitamin D, is a mature assay exposed to pricing pressure. The company estimated in October 2025 that around 2% of annual revenue was at short-term risk in China, with a further 3% to 4% at medium-term risk as customers face pressure to switch to cheaper local antibodies.

Currency is a persistent swing Factor given that more than half of sales are dollar-linked; sterling strength cut interim revenue by roughly £240k. The Siemens troponin royalty stream will "terminate for contractual reasons in June 2032", putting a finite horizon on a key income line unless volumes grow first.

The dividend deserves scrutiny. FY25 payouts exceeded Earnings and cash fell by £0.9m, so a further revenue decline leaves less room to maintain 150p a year without eroding the balance sheet. The Alzheimer's opportunity depends on customers' regulatory decisions that Bioventix does not control, and with only 43.5% of shares in public hands, Liquidity can be thin.

Outlook

Bioventix is a business in transition: a highly profitable but ex-growth core portfolio funding a still-small neurology franchise with momentum. The October results will show whether the "modest decline" guidance held, how far tau royalties climbed in the second half, and whether troponin volumes have begun to respond to Siemens' expanded label.

The appointment of Chris Yates, former Abingdon Health chief executive, as a non-executive director from 1 March 2026 adds commercial diagnostics experience to a compact board. The data points to monitor are pTau217 assay adoption, dollar exchange rates, Chinese Demand for the vitamin D antibody and the dividend decision that accompanies the full-year numbers.